Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective, mono centric, exploratory study to assess the incidence of a genomic alteration: NTRK gene fusion, in adult gliomas and brain metastases.
Retrospective mono centric study of medical data (clinical, histological, molecular and imaging) from medical records and analysis of available excisional tissue samples.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glioma | (20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas) |
| |
| Brain metastasis | The "brain metastasis" cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glioma data collection | Other | Glioma data collection |
| |
| Brain metastasis data collection |
| Measure | Description | Time Frame |
|---|---|---|
| NTRK Fusion | Incidence of NTRK gene fusion identified by RNAseq in glioma and brain metastasis tumour samples. | through study completion, an average of 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| NTRK Fusion identification in brain metastasis and primary tumor | Incidence of NTRK gene fusion identified in matched pairs of brain metastasis and primary tumor; | through study completion, an average of 12 months |
| Progression-free survival in patients with NTRK gene fusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients operated for glioma or brain metastasis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Philippe METELLUS, MD PD | Hôpital Privé Clairval | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Privé Clairval | Marseille | 13009 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
The genomic analyses will be performed on tumour samples collected in routine practice during brain tumour removal surgery (glioma or brain metastasis) and the clinico-biological data will be collected from the medical records.
| Other |
Brain metastasis data collection |
|
Progression-free survival in patients with NTRK gene fusion. Progression-free survival is defined as the time from the date of initial surgery to the date of diagnosis of progression. Progression will be defined according to the RANO criteria at 6 months |
| Month 6 |
| Progression-free survival in patients with NTRK gene fusion | Progression-free survival in patients with NTRK gene fusion. Progression-free survival is defined as the time from the date of initial surgery to the date of diagnosis of progression. Progression will be defined according to the RANO criteria at 12 months | Month 12 |
| Overall survival in patients with NTRK gene fusion. | Overall survival in patients with NTRK gene fusion. Overall survival is defined as the time from the date of initial surgery to the date of death (or the date of last news) of the patient. | through study completion, an average of 12 months |
| Specific radiological criterion (T1) | Specific radiological criteria (T1) in patients with NTRK gene fusion in gliomas and brain metastases | through study completion, an average of 12 months |
| Specific radiological criterion (T2) | Specific radiological criteria (T2) in patients with NTRK gene fusion in gliomas and brain metastases | through study completion, an average of 12 months |
| Specific radiological criterion (FLAIR) | Specific radiological criteria (FLAIR) in patients with NTRK gene fusion in gliomas and brain metastases | through study completion, an average of 12 months |
| Specific radiological criterion (perfusion) | Specific radiological criteria (perfusion) in patients with NTRK gene fusion in gliomas and brain metastases | through study completion, an average of 12 months |
| Incidence of other genomic alterations | Incidence of other genomic alterations identified by RNAseq, associated with the incidence of NTRK gene fusion | through study completion, an average of 12 months |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |